Stock Price of Biocept, Inc. (BIOC) Increases 54.9%

Biocept, Inc.s in-depth stock price analysis indicates that the stock price has rallied 182.14% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 36.19% . Looking at the past 52 week period, the stock price is down -43.58% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Biocept, Inc. has a negative value of -79.98 compared to overall market performance. Biocept, Inc. (NASDAQ:BIOC) has climbed 54.9% in the past week and advanced 13.4% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 53.65% and the outperformance has advanced to 11.37% for the last 4 weeks period.

Biocept, Inc. (NASDAQ:BIOC) : On Friday heightened volatility was witnessed in Biocept, Inc. (NASDAQ:BIOC) which led to swings in the share price. The stock opened for trading at $2.46 and hit $2.7599 on the upside , eventually ending the session at $2.37, with a gain of 8.22% or 0.18 points. The heightened volatility saw the trading volume jump to 14,979,279 shares. The 52-week high of the share price is $5.640005 and the company has a market cap of $41 million. The 52-week low of the share price is at $0.7401 .

Company has reported several Insider transactions to the SEC, on Oct 21, 2016, Michael W. Nall (CEO) purchased 36,363 shares at 1.10 per share price.On Oct 21, 2016, Marsha Alpert Chandler (director) purchased 4,545 shares at 1.10 per share price.On Oct 21, 2016, Timothy Kennedy (CFO) purchased 36,363 shares at 1.10 per share price.

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California.


Share this post

Leave a Reply